Leveraging the semantic web and natural language processing to enhance drug-mechanism knowledge in drug product labels

IHI'10 - Proceedings of the 1st ACM International Health Informatics Symposium

Volumn , Issue , 2010, Pages 492-496

  Boyce, Richard ^a   Harkema, Henk ^a   Conway, Mike ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

drug product labeling; drug drug interactions; mash up; semantic web

Indexed keywords

ADVERSE DRUG EVENTS; DRUG-DRUG INTERACTIONS; HEALTH CARE PROVIDERS; MASH-UP; NATURAL LANGUAGE PROCESSING; PRODUCT LABELING; PRODUCT LABELS; SEMANTIC WEB TECHNOLOGY;

COMPUTATIONAL LINGUISTICS; HEALTH; HEALTH CARE; INFORMATION SCIENCE; KNOWLEDGE MANAGEMENT; NATURAL LANGUAGE PROCESSING SYSTEMS; SEMANTIC WEB; SEMANTICS;

DRUG INTERACTIONS;

EID: 78650937154     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1145/1882992.1883070     Document Type: Conference Paper

References (27)

1. Amgen. SENSIPAR (cinacalcet hydrochloride) tablet, coated . FDA-approved drug product labeling, 12 2008. Last accessed on DailyMed 06/29/2009.
2. Apotex. fluconazole (fluconazole) solution. FDA-approved drug product labeling, 01 2007. Last accessed on DailyMed 05/22/2010.
3. R. Boyce, C. Collins, J. Horn, and I. Kalet. Modeling drug mechanism knowledge using evidence and truth maintenance. IEEE Transactions on Information Technology in Biomedicine, 11(4):386-397, 2007.
4. R. Boyce, C. Collins, J. Horn, and I. Kalet. Computing with evidence part I: A drug-mechanism evidence taxonomy oriented toward confidence assignment. J Biomed Inform, 42(6):979-989, 2009.
5. R. Boyce, C. Collins, J. Horn, and I. Kalet. Computing with evidence part II: An evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform, 42(6):990-1003, 2009.
6. W. W. Chapman, W. Bridewell, P. Hanbury, G. F. Cooper, and B. G. Buchanan. A simple algorithm for identifying negated findings and diseases in discharge summaries. J Biomed Inform, 34(5):301-10, Oct 2001.
7. Y.-F. Chen, A. Avery, K. Neil, C. Johnson, M. Dewey, and I. Stockly. Incidence and possible causes of prescribing potential hazardous/contraindicated drug combinations in general practice. Drug Safety, 28:67-80, 2005.
8. Committee on Identifying and Preventing Medication Errors. Preventing medication errors. Technical report, Institute of Medicine, 2006. 0309102685.
9. U. Congress. Code of Federal Regulations 21 Part 201, chapter Labeling. Washington, DC: US Government Printing Office, 2010.
10. U. Congress. Code of Federal Regulations 21 Part 201.56, chapter Requirements on content and format of labeling for human prescription drug and biological products. Washington, DC: US Government Printing Office, 2010.
11. T. Fayruzov, M. D. Cock, C. Cornelis, and V. Hoste. Linguistic feature analysis for protein interaction extraction. BMC Bioinformatics, 10:374, 2009. PMID: 19909518.
12. G.D.-Searle-LLC. COVERA-HS (verapamil hydrochloride) tablet, extended release . FDA-approved drug product labeling, 04 2010. Last accessed on DailyMed 05/22/2010.
13. Global-Pharmaceuticals. GEMFIBROZIL tablet, coated . FDA-approved drug product labeling, 09 2009. Last accessed on DailyMed 05/22/2010.
14. J. Gurwitz, T. Field, J. Judge, P. Rochon, L. Harrold, C. Cadoret, M. Lee, K. White, J. LaPrino, J. Erramuspe-Mainard, M. DeFlorio, L. Gavendo, J. Auger, and D. Bates. The incidence of adverse drug events in two large academic long-term facilities. Am J Med, 118:251-258, 2005.
15. Internal. FDA guideline: Drug interaction studies - study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf, Sept. 2006. Last Accessed: 03/31/2010.
16. IVAX. cimetidine (Cimetidine) tablet, film coated . FDA-approved drug product labeling, 08 2008. Last accessed on DailyMed 12/28/2009.
17. D. N. Juurlink, M. Mamdani, A. Kopp, A. Laupacis, and D. A. Redelmeier. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA, 289(13):1652-1658, 2003.
18. P. Marroum and J. Gobburu. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet., 41(3):161-9, 2002.
19. G. Móra, R. Farkas, G. Szarvas, and Z. Molnár. Exploring ways beyond the simple supervised learning approach for biological event extraction. In BioNLP '09: Proceedings of the Workshop on BioNLP, pages 137-140, Morristown, NJ, USA, 2009. Association for Computational Linguistics.
20. Mutual. PROPAFENONE HYDROCHLORIDE tablet, film coated . FDA-approved drug product labeling, 07 2009. Last accessed on DailyMed 05/15/2010.
21. Mylan. cimetidine (Cimetidine) tablet, film coated . FDA-approved drug product labeling, 07 2007. Last accessed on DailyMed 12/28/2009.
22. S. H. Preskorn. How drug-drug interactions can impact managed care. The American Journal of Managed Care, 10(6 Suppl):S186-S198, July 2004.
23. Teva. trimethoprim (Trimethoprim) tablet. FDA-approved drug product labeling, 06 2008. Last accessed on DailyMed 05/22/2010.
24. Teva Pharmaceuticals. fluconazole (fluconazole) Teva. FDA-approved drug product labeling, 10 2006. Last accessed on DailyMed 05/22/2010.
25. Watson. mexiletine hcl (Mexiletine hydrochloride) capsule . FDA-approved drug product labeling, 04 2008. Last accessed on DailyMed 05/22/2010.
26. D. S. Wishart, C. Knox, A. C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, and J. Woolsey. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res, 34(Database issue):D668-D672, 2006.
27. R. Yuan, T. Parmelee, J. D. Balian, R. S. Uppoor, F. Ajayi, A. Burnett, L. J. Lesko, and P. Marroum. In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin Pharmacol Ther, 66(1):9-15, 1999.